Pinnacle Medicines | $89,000,000 | (Mar 27, 2026)
CurrentClient | $1,250,000 | (Mar 27, 2026)
Mirage | $75,000,000 | (Mar 27, 2026)
Certified by Founder
Lodge
Shinobi Therapeutics
start up
United States
- South San Francisco, CA
- 13/12/2023
- Series A
- $51,000,000
Shinobi Therapeutics is developing a new class of hypoimmune CD8ab iPS-T cells for cancer and beyond by using immune evasion to unlock the full potential of iPSCs.
- Industry Biotechnology Research
- Website https://www.shinobitx.com/
- LinkedIn https://www.linkedin.com/company/shinobitx/about/
Related People
Dan KempFounder
United States -
New York City Metropolitan Area
Accomplished BioPharma Executive with experience in drug discovery (Novartis), translational and clinical development (Merck), sell-side, buy-side and M&A transactional BD (Takeda), Executive oversight (GammaDelta Therapeutics, Adaptate Therapeutics) and Operational Leadership (Cell Therapies at Takeda).
Scalvy | $13,900,000 | (Mar 27, 2026)
SIGMAS | $1,000,000 | (Mar 27, 2026)
VITL | $7,500,000 | (Mar 27, 2026)
Payy | $6,000,000 | (Mar 27, 2026)
Conntour | $7,000,000 | (Mar 27, 2026)
KilgourMD | Undisclosed Amount | (Mar 27, 2026)
Terrestrial | $50,000,000 | (Mar 27, 2026)
Krane | $9,000,000 | (Mar 26, 2026)
Zalos (YC F25) | $3,600,000 | (Mar 26, 2026)